Variable Effects of Voriconazole (VRC) and Caspofungin (CAS) on Cytokine and Chemokine Release by Human Monocytes (MNCs) in Response to Aspergillus Fumigatus (AF).

M. SIMITSOPOULOU 1,2, M. DALAKIOURIDOU 1, T. KONSTANTINOU 1, P. SIOURDA 2, J. IOANNIDIS 2, A. ORFANOU 2, T. WALSH 3, E. ROILIDES1,3;

Author address: 

1Aristotle Univ., Thessaloniki, Greece, 2Technological Inst., Thessaloniki, Greece, 3NCI, NIH, Bethesda, MD.

Abstract: 

Background: VRC, an ergosterol synthesis inhibitor, and CAS, a fungal cell-wall glucan synthesis inhibitor, constitute new potent therapies for invasive aspergillosis with different mechanisms of activity. We therefore studied their effects on release of cytokines and chemokines by MNCs in response to AF. Methods: THP1 monocytic cell line was used as a source of MNCs. 106/mL AF hyphal fragments (HF) were obtained by sonication. 106 MNCs were incubated with HF at E:T ratio 10:1 with or without 0.1 μg/mL VRC and 0.05 μg/mL CAS at 37oC for 6h. Culture supernatants were collected and IL-1β , IL-10, IL-12, MCP-1, MIP-1β , and TNF-α were measured by ELISA. Statistical analysis of 5 (VRC) and 5 (CAS) experiments was performed using ANOVA with Dunnett test for multiple comparisons. Results: (*p
2006

abstract No: 

M-1785

Full conference title: 

46th Interscience Conference on Antimicrobial Agents and Chemotherapy
    • ICAAC 46th